New Veeva Vault eTMF feature uses artificial intelligence for greater productivity and compliance
PLEASANTON, CA — Oct. 13, 2021 — Veeva Systems (NYSE: VEEV) today announced the TMF Bot, a new Veeva Vault eTMF feature that uses artificial intelligence (AI) to streamline TMF management and accelerate trial execution. The TMF Bot uses a customer’s existing data to classify documents automatically, quickly, and accurately.
“We are processing documents more quickly and more efficiently with Veeva Vault eTMF and the TMF Bot,” said Stephen van Arcken, senior clinical oversight lead at Cerevel Therapeutics. “With less manual intervention, we can save time and resources while increasing the overall quality of the TMF.”
Automating trial processes with the TMF Bot can reduce the administrative burden on study teams and help alleviate the challenges of misfiled or misclassified documents within the TMF. This allows users to focus on high-value activities and improves TMF accuracy, timeliness, and completeness.
“Complexity across the clinical landscape continues to grow, driving companies to new and innovative solutions that can transform trial execution,” said Jason Methia, vice president, Veeva Vault Clinical Operations strategy. “Using AI in TMF is an impactful and practical way to reduce administrative tasks in clinical trials, driving improved compliance and efficiency. The TMF Bot has auto-classified more than 40,000 documents across six customers since it was released, saving hundreds of hours in processing time.”
Vault eTMF is part of the Veeva Vault Clinical Operations Suite, enabling companies to share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle. The TMF Bot is available now and included in Vault eTMF.
Hear Cerevel share tips and tricks to get started with the TMF Bot and learn more about the new feature at the upcoming Veeva R&D and Quality Summit Connect, October 14, 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2021. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.